CiplaQCIL to enter the private market in Uganda

By August 26, 2020Company News

As part of CiplaQCIL’s expansion strategy, the company has acquired Quality Chemical Ltd.’s distribution arm of the Cipla India manufactured range of prescription medicines in Uganda. The acquisition takes the form of a transfer of assets of Quality Chemicals Limited, specifically the sales staff overseeing the human healthcare portfolio, and is expected to boost the company’s sales growth by expanding its product range while unlocking new business opportunities in the retail distribution market.

CEO of CiplaQCIL, Nevin Bradford, said: “The businesses revenue streams have previously primarily been focused on government and donor-funded sales. This recent acquisition is an exciting entry for the business into the private retail pharmaceutical market in Uganda.”

CiplaQCIL will import and distribute the range of medicines manufactured in India by Cipla Limited as well as those manufactured locally in Uganda by CiplaQCIL. The India range includes medicines for asthma, chronic obstructive pulmonary disease (COPD), diabetes, infections, gastroenterology, and cardiovascular disease. Distribution of the medicines will commence immediately from CiplaQCIL’s warehouse in Luzira.

Bradford said: “As part of our Africa for Africa strategy and commitment to “caring for life”, we’re proud that CiplaQCIL is able to manufacture and now import and distribute lifesaving medicines to ensure that Ugandans and people from other neighboring countries have easy access to quality, affordable medicines.”

Ends